Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Coor signs agreement with Novozymes in Denmark

Needs-based maintenance, advanced technology and long-term partnership based on close cooperation were essential when Novozymes requested tenders for operation and maintenance of their facilities in Denmark. Coor´s tender won.Coor has won a five-year contract with Novozymes, a global leader in biology, on development and delivery of operating and maintenance for Novozymes 275,000 sqm. buildings in Bagsværd, Kalundborg and Fuglebakken in Copenhagen. Previously, Novozymes outsourced all property services to a variety of suppliers, but the choice of Coor as strategic partner fulfils the

Information Builders Offers iWay Big Data Integrator on Microsoft Azure Marketplace Cloud

Enterprises Can Harness Big Data’s Potential With This Native Hadoop Solution for Data Lake Creation and ManagementNew York, NY, – March 23, 2017 – Information Builders, a leader in business intelligence  (BI) and analytics, data integrity, and integration solutions, today announced that it is offering its iWay Big Data Integrator (iBDI) product via the cloud on the Microsoft Azure Marketplace. The solution simplifies the creation, management, and use of Hadoop-based data lakes, providing a modern integration and management approach

Alma Media’s share-based incentive scheme commencing in 2017

Alma Media Corporation         Other information disclosed according to the rules of the Exchange  23 March 2017 at 10:00 a.m. (EET) ALMA MEDIA’S SHARE-BASED INCENTIVE SCHEME COMMENCING IN 2017 (LTI 2015 III) In 2015, the Board of Directors of Alma Media Corporation approved the establishment of a long-term share-based incentive scheme for the key management of Alma Media (hereinafter referred to as “LTI 2015”). The objective of LTI 2015 is to align the interests of the participants with those of Alma Media’s shareholders by creating a long-term equity interest for the participants

Notice of the Annual General Meeting of Formpipe Software AB (publ)

The shareholders of Formpipe Software AB (publ), company reg. no. 556668-6605, (the “Company”) are hereby invited to attend the Annual General Meeting (AGM) to be held on Tuesday, 25 April 2017, at 14.00 at the Company’s premises at Sveavägen 168, Stockholm. Notification of attendance at the AGMShareholders who wish to attend the AGM must: · both be registered on Wednesday, 19 April 2017 in the register of shareholders kept by Euroclear Sweden AB; · and notify their intended participation to the Company by post to Formpipe Software AB, Årsstämma 2017, Box 23131, 104 35

Planmeca announces new efficient and cost-effective milling unit

Dental equipment manufacturer Planmeca expands its extensive CAD/CAM product range with a new entry-level milling unit. Named Planmeca PlanMill® 30 S, the new milling unit has been developed for dental businesses looking for efficient, accurate, and cost-effective milling solution.The Planmeca PlanMill® 30 S is a high-accuracy entry-level unit, which guarantees a professional entry to the world of CAD/CAM technology. The unit has been designed for the chairside fabrication of metal-free dental restorations and appliances. “The Planmeca PlanMill 30 S is a great addition to Planmeca’s CAD/

NeuroVive Pharmaceutical AB publishes 2016 Annual report

Lund, Sweden, March 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for 2016 is now available on the company’s website www.neurovive.com .About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 27, 2017, at 4 pm at Medicon Village, Scheelevägen 2 in Lund, Sweden.Please see the attached notification, which is being announced within short in Svenska Dagbladet and Post- och Inrikes Tidningar. Lund, March 23, 2017NeuroVive Pharmaceutical AB (PUBL)THE BOARD OF DIRECTORS About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines

Capio’s Nomination Committee proposes Board members for the Annual General Meeting 2017

The Nomination Committee of Capio AB (publ) has resolved to propose to the Annual General Meeting (AGM) to be held on 3 May 2017 the election of Michael Wolf, Gunilla Rudebjer and Karl Åberg as new Board members. Furthermore, the Nomination Committee proposes re-election of the Board members Gunnar Németh, Fredrik Näslund, Birgitta Stymne Göransson, Pascale Richetta and Michael Flemming. The Nomination Committee proposes election of Michael Wolf as new Chairman of the Board.Anders Narvinger and Gun Nilsson have declined re-election. ”I am satisfied with Capio now being established on

ChromoGenics share and warrant TO1 start trading today on Nasdaq First North, Stockholm

ChromoGenics AB (publ) shares and warrants start trading today March 23 2017 on Nasdaq First North Stockholm. ChromoGenics is a leading provider of dynamic glass for solar control. The company focuses on window and facade glass for commercial buildings and addresses architects, real estate owners and construction companies.In the recently completed rights issue (the "Offering"), a total of 13,800,000 shares and 13,921,312 TO1 were issued. The number of shares may be increased by a maximum of 121 312 for the event that it decided allotment option would be fully utilized. The price per "Unit"

Welcome to the Annual General Meeting of Studsvik AB

Studsvik AB (publ), corporate identity number 556501-0997, gives notice to attend the Annual General Meeting to be held on Thursday April 27, 2017 at 16.00 at the World Trade Center, Klarabergsviadukten 70/Kungsbron 1 in Stockholm. Registration for the Annual General Meeting starts at 15.00.Registration and notification of attendance Shareholders who wish to participate in the Annual General Meeting must ·  be registered in the share register kept by Euroclear Sweden AB by Friday, April 21, 2017, and ·  give notification to the company by Friday, April 21, 2017 at the latest.

Badger Explorer ASA – Final results of Subsequent Offering II

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATESReference is made to the stock exchange releases from Badger Explorer ASA ("BXPL" or the "Company") published 15th February 2017 and 20th March 2017 regarding the subsequent offering (the “Subsequent Offering II”) of up to 80,000,000 new shares in the Company at a subscription price of NOK 0.50 per share (the "Offer II Shares”). The final results show that a total of 61.7 million shares were subscribed for. The Board of Directors resolved the

Cherry iGaming & ComeOn! will brand the new Business Area - ComeOn!

As part of the integration project between Cherry iGaming and ComeOn!, the Cherry business area will resume the brand ComeOn! moving forward, which will be fully utilised across the business from April 1st, 2017. Branding the company ComeOn! will re-emphasise its operational independence, aligning with other business areas owned and built up by Cherry. “We are building a Business Area, merging Cherry iGaming and ComeOn !, with a number of brands within it and setting a new unified culture and actionable values. We therefore wanted to take this opportunity to have a really good think

European patent granted for Idogen’s vaccine technology

Idogen AB (”Idogen”) announces that the European Patent Office (”EPO”) will formally grant a patent application, covering the company’s tolerogenic vaccine technology. The EPO approval strengthens the company’s patent portfolio for the vaccine technology. A patent in the same patent family has already been granted in Japan and a Notice of Allowance has been received from the USA.The European Patent Office issued in January 2017 a “Notice of intention to grant” and will now formally grant Idogen’s Patent Application relating to induction of IDO for treatment of autoimmune diseases and

Selvaag Bolig ASA: Purchase of treasury shares

Selvaag Bolig ASA purchased 3 832 treasury shares on 22 March 2017. The shares were purchased at an average price of NOK 39.06. The shares were purchased for the company's share programmes for employees. After the transaction, Selvaag Bolig owns 1 106 882 treasury shares. Further information fromSverre Molvik, CFO, Selvaag Bolig ASATelephone: +47 401 00 585, e-mail: smo@selvaagbolig.no Selvaag Bolig ASA is a residential property developer controlling the entire value chain from acquisition of land to sale of homes. The company has several thousand homes under development at any

Publication of Biohit Oyj Annual Report 2016

Biohit Oyj Annual Financial Report March 23, 2017 at 9:30 am local time (EET) Biohit Oyj’s Annual Report 2016 is published today in PDF format. The annual report contains financial statements for 2016, the Report of the Board of Directors and Corporate Governance Statements. Annual report is published in Finnish and English, and it can be read and downloaded from Biohit company website www.biohithealthcare.com/investors. Attachment: Biohit Oyj Annual Report 2016 Additional information: CEO Semi Korpela, Biohit Oyjtel. +358 9 773 861investor.relations@biohit.fiwww.

Planmeca and CephX Technologies LTD launch service for automatic cephalometric tracing and analysis

The Finnish dental equipment manufacturer Planmeca has teamed up with CephX Technologies LTD to offer a new service for automatic cephalometric tracing and analysis. Utilising machine learning technology and artificial intelligence, the service has been designed to help the daily work of orthodontic practitioners around the world. It automatically delivers cephalometric tracing and analyses with a few clicks and in a matter of seconds when integrated into the Planmeca Romexis® dental imaging software. Planmeca and CephX Technologies LTD today announced the launch of an automatic

Oulun Energia is building a solar energy revolution in the dark North

Surprisingly many large or middle-sized Finnish companies could generate a significant amount of the used electric power by emission-free and genuinely environment-friendly solar energy.Oulun Energia Oy is a forerunner of Finnish electric power products and services. It has invested heavily in solar energy production and is aiming at efficiently realising and promoting the cost efficiency of solutions that utilise solar energy to both companies and consumers. “Many people find it surprising that in Oulu, Oulun Energia’s home town, you can receive the same amount of solar energy annually

Concentric AB secures order for new electric oil pump technology with leading global OEM

Concentric AB has recently received an order from a global OEM of heavy trucks and buses to produce electric oil pumps for their hybrid applications. Production will start in the second half of 2018, and is expected to generate total revenues of approximately MSEK 38 across Europe ramping up over an 8 year period, reaching a mature volume of 8,000 p.a. in 2026.This exciting new product reinforces the company’s reputation for reducing fuel consumption, increasing system efficiency, providing high power density and reducing noise. Concentric's electric oil pump offers system power savings

Munksjö site in Rottersac, France, receives ISO 22000 Food Safety certification

MUNKSJÖ OYJ, PRESS RELEASE 23 March 2017 at 8.00 am CETHelsinki, Finland Munksjö site in Rottersac, France, receives ISO 22000 Food Safety certification Munksjö, a world-leading manufacturer of advanced specialty papers announces that its Rottersac production site in France has been awarded ISO 22000:2005 certification by SGS for its Food Safety Management System. A large proportion of the technical papers manufactured at the Rottersac mill include products for the food packaging industry. These packaging papers serve various end-use applications in the bakery, confectionery,

Notice of Annual General Meeting of Mr Green & Co AB (publ)

The shareholders of Mr Green & Co AB (publ), Corporate Registration Number 556883-1449 (“the Company”) are hereby invited to the Annual General Meeting on Monday, 24 April 2017 at 5.00 p.m. at Wallenbergsalen, IVA, Grev Turegatan 16 in Stockholm, Sweden. A. Right to participate in the MeetingShareholders who wish to participate in the Meeting must be included in the share register maintained by Euroclear Sweden AB as of Tuesday, 18 April 2017, and notify the Company of their participation not later than 18 April 2017 at the following address: Annual General Meeting, Mr Green & Co AB,

Annual general meeting in Magnolia Bostad 2017

The Magnolia Bostad AB board of directors has resolved to convene an annual general meeting of shareholders to be held Wednesday April 26, 2017. Further details on the proposals are found in the notice convening the meeting which is found below. The notice is expected to be published in the Swedish Official Gazette (Post- och Inrikes Tidningar) and on the company’s website within the next few days. NOTICE OF ANNUAL GENERAL MEETING MAGNOLIA BOSTAD AB The Annual General Meeting of Magnolia Bostad AB will be held on Wednesday, 26 April 2017 at 2.00pm at Berns, Berzelii Park, Stockholm.

Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013

Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the first phase I study with ADC-1013, a human, monospecific, agonistic IgG1 antibody for cancer immunotherapy, has been completed. Alligator will host a live webcast for analysts, investors and media today, 23th March 2017, at 10.30 CET.The phase I trial, which began in April 2015, is a dose-escalation study involving intratumoral and intravenous administration of ADC-1013 at five clinical sites in Sweden, Denmark and the UK (ClinicalTrials.gov: NCT02379741). The study is sponsored by Alligator and

Deflamo AB: Kallelse till årsstämma 2017

This message is only published in Swedish. For more information, see contact information below. Kallelse till årsstämma i Deflamo AB (publ) Deflamo AB (publ) ("Bolaget") håller årsstämma torsdagen den 27 april 2017 kl. 11.00 i Bolagets lokaler på Höjdrodergatan 32 i Malmö. Rätt att delta Rätt att delta i bolagsstämman har den som: dels är registrerad som aktieägare i den av Euroclear Sweden AB förda aktieboken fredagen den 21 april 2017; dels anmäler sitt deltagande på stämman hos Bolaget senast fredagen den 21 april 2017 kl. 16.00 under adress Deflamo AB, "Årsstämma",

Targovax ASA moves share listing to Oslo Børs

Oslo, Norway, 23 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that its shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. The Company was previously listed on Oslo Axess, a regulated and licensed market under the auspices of the Oslo Stock Exchange. Since listing the shares of Targovax on Oslo Axess in July 2016, the Company has achieved several milestones, including: · Encouraging top line two-year

There are no items matching the current filter
There are no more items matching the current filter
Back to top